Eloralintide for Obesity and Type 2 Diabetes
(ENLIGHTEN-10 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called eloralintide to determine its effectiveness for people with obesity and type 2 diabetes who are at risk for heart problems. The goal is to assess whether it works better than a placebo and is safe to use. Suitable candidates for this trial have type 2 diabetes, a history of unsuccessful diets, and are on stable diabetes medication. Participants should also have a BMI of 25 or higher and be concerned about heart health risks. As a Phase 3 trial, this treatment is in the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking therapy.
Is there any evidence suggesting that eloralintide is likely to be safe for humans?
Research has shown that eloralintide appears safe based on earlier studies. In one study, participants generally handled the treatment well, with no serious side effects reported. Eloralintide helps control appetite and food intake, making it a candidate for weight management in people with obesity and type 2 diabetes. Another study found that most participants had no trouble taking eloralintide. These findings suggest that eloralintide might be safe for humans, but ongoing studies will help confirm this.12345
Why do researchers think this study treatment might be promising?
Eloralintide is unique because it offers a novel approach to managing obesity and type 2 diabetes by being administered subcutaneously, which may enhance patient compliance compared to oral medications. Unlike standard treatments like metformin or GLP-1 receptor agonists, Eloralintide might offer different metabolic benefits, potentially leading to improved weight loss and blood sugar control. Researchers are excited about Eloralintide because it could provide a new mechanism of action, offering hope to those who haven't achieved desired results with current medications.
What evidence suggests that eloralintide might be an effective treatment for obesity and type 2 diabetes?
Research has shown that eloralintide, which participants in this trial may receive, holds promise for individuals with obesity and type 2 diabetes. In earlier studies, participants taking eloralintide lost up to 20.9% of their body weight. It also reduced A1C levels, a measure of blood sugar control, by 2.2%. These findings suggest that eloralintide could aid in weight management and improve blood sugar levels for those with type 2 diabetes.678910
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adults who are overweight or obese, have type 2 diabetes, and are at higher risk for heart problems. People with these conditions may be eligible to join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive eloralintide or placebo subcutaneously once weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Eloralintide
Trial Overview
The study compares a new drug called eloralintide to a placebo (inactive treatment) to see if it helps people lose weight and manage their diabetes while monitoring safety. Participants are randomly assigned to either group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive eloralintide subcutaneously (SC)
Participants will receive placebo SC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Citations
1.
hcplive.com
hcplive.com/view/investigative-amylin-agonist-eloralintide-proves-superiority-to-placebo-in-weight-managementInvestigative Amylin Agonist Eloralintide Proves Superiority ...
Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes. Read ...
Eloralintide + Tirzepatide for Obesity · Info for Participants
Tirzepatide, a dual receptor agonist for type 2 diabetes, significantly reduces body weight compared to placebo, with an average weight loss of up to 11.8 kg ...
3.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT07282600/a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-and-type-2-diabetesA Study of Eloralintide (LY3841136) in Participants With ...
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in ...
4.
clinicaltrials.eu
clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-eloralintide-in-adults-with-obesity-or-overweight-and-type-2-diabetesA study to evaluate the efficacy and safety of eloralintide ...
It is being studied to see how well it helps adults who are overweight, have obesity, or have type 2 diabetes to lose body weight. LY3841136 ...
A Study of Eloralintide (LY3841136) and ... - Lilly Trials
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in ...
Eloralintide, a selective, long‐acting amylin receptor agonist ...
Here, we present the results of a Phase 1b multiple‐ascending dose trial exploring the safety and tolerability of repeated doses of eloralintide ...
Lilly's selective amylin agonist, eloralintide, demonstrated ...
"These Phase 2 data suggest eloralintide could offer a promising tolerability profile without compromising on efficacy, underscoring the ...
A Study of Eloralintide (LY3841136) in Participants With ...
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes.
NCT07392190 | A Study of Eloralintide (LY3841136) in ...
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or ...
10.
ctv.veeva.com
ctv.veeva.com/study/a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-and-type-2-diabetesA Study of Eloralintide (LY3841136) in Participants With ...
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.